IJE Software logoIJEsoft
ServicesPortfolioPricingAboutCase StudyStackNewsBlogPartnerPH NewsMarketsContactGet in touch
← Back to Philippines Business News
Manila Times Business

LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Now Available in Japan for Patients with Early Alzheimer’s Disease

The First and Only Anti-Amyloid Treatment in Japan that Enables At-Home Administration TOKYO and CAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that "LEQEMBI® Pen”, the subcutaneous (SC) formulation of "LEQEMBI®” (generic name: lecanemab) has been launched in Japan. LEQEMBI Pen was approved as a new route of administration in Japan on September 16, 2026, and was published in Japan’s National Health Insurance (NHI) Drug Price Lis

Context & Analysis

The arrival of a home-administered anti-amyloid therapy in Japan is a signal for Philippine healthcare players that the next phase of Alzheimer’s care may be less hospital-centric. For years, advanced treatments for neurodegenerative diseases have depended on infusion centers, specialist supervision, and patient travel, all of which strain clinic scheduling and limit reach outside Metro Manila. A pen or autoinjector format, if it eventually clears local regulatory review, could shift part of treatment into homes, pharmacy-supported programs, or private clinics with trained nurses. That changes the business map: pharmaceutical distributors, logistics firms, medical consumables suppliers, home-health agencies, and even real estate developers of senior living facilities may need to prepare for a more decentralized model.

For Filipino consumers, the practical issue is access and trust. A treatment that can be given at home may reduce time away from work or caregiving, but it also raises questions about cold-chain handling, correct injection technique, side-effect monitoring, and emergency response. Patients and families will likely seek clear guidance from doctors, pharmacists, and insurers before adopting such a product. In the Philippines, where out-of-pocket healthcare spending remains significant, any therapy for early Alzheimer’s disease will face scrutiny not only on clinical value but on affordability and reimbursement pathways.

For Philippine businesses, the broader lesson is that global biotech innovation is moving from product launch to delivery design. Eisai and Biogen’s Japan rollout suggests competition will increasingly reward companies that can make complex therapies easier for patients and health systems to use. Local firms should watch how regulators, payers, and hospital groups respond to at-home biologics, especially around training, pharmacovigilance, and supply assurance. The next signal to monitor is whether similar formats gain traction in other Asian markets and whether Philippine regulators and insurers begin setting expectations for home-based specialty care.

Analysis by IJE Software — original commentary on the story above.

This is an excerpt. Read the full article at the original source:

Source: manilatimes.net

More from Manila Times Business

EZVIZ Announces UK Black Friday Savings of Up to 40% on Smart Home and Entry Products

4h ago

Share Buy-back Programme - Transactions Week 46

4h ago

Lucas Malone Releases Dark Romantic Comedy-Thriller Hard Count, Garnering Critical and Awards Recognition

4h ago

Share buyback programme - week 46

4h ago

Your Daily Briefing

AI business companion — delivered every morning

Markets, PH news, financial insights, and devotionals — curated by AI and sent at 7 AM PHT. Pick your topics below.

Devotionals
Blog Topics
HR & Workforce
Real Estate & Property
News & Markets

1 topic selected